FDA Greenlights First-ever Treatment for Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. has received FDA approval for XDEMVY™ (lotilaner ophthalmic solution) 0.25% as a therapeutic solution for Demodex blepharitis,
Read moreTarsus Pharmaceuticals, Inc. has received FDA approval for XDEMVY™ (lotilaner ophthalmic solution) 0.25% as a therapeutic solution for Demodex blepharitis,
Read moreVarda Space Industries, a California-based startup, is venturing into the realm of pharmaceutical manufacturing in microgravity with the goal of
Read moreEli Lilly and Company and DICE Therapeutics, Inc. have signed a definitive agreement for Lilly to acquire DICE for approximately $2.4
Read moreMcMaster University and the Massachusetts Institute of Technology researchers using artificial intelligence (AI) have discovered a new type of antibiotic
Read moreKrystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read moreCoya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read moreAccording to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read moreChiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreJanssen has received its first worldwide approval for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) as EC Authorized treatment
Read moreGSK has entered into an agreement to acquire BELLUS Health, a Canadian late-stage biopharmaceutical company, for a total consideration of
Read more